公开(公告)号：US07989457B2

公开(公告)日：2011-08-02

申请号：US11569273

申请日：2005-05-13

申请人： Mark Donald Chappell ,  Scott Eugene Conner ,  Isabel Cristina Gonzalez Valcarcel ,  Jason Eric Lamar ,  Jianke Li ,  Julie Sue Moyers ,  Rebecca Anne Owens ,  Allie Edward Tripp ,  Guoxin Zhu

发明人： Mark Donald Chappell ,  Scott Eugene Conner ,  Isabel Cristina Gonzalez Valcarcel ,  Jason Eric Lamar ,  Jianke Li ,  Julie Sue Moyers ,  Rebecca Anne Owens ,  Allie Edward Tripp ,  Guoxin Zhu

IPC分类号： C07D239/26 ,  A61K31/505

CPC分类号： C07D213/16 ,  C07D213/26 ,  C07D213/30 ,  C07D213/32 ,  C07D213/643 ,  C07D239/26 ,  C07D401/04

摘要： The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

摘要翻译： 本发明公开了具有胰高血糖素受体拮抗剂或反向激动剂活性的式（I）的新化合物或其药学上可接受的盐，以及制备这些化合物的方法。 在另一个实施方案中，本发明公开了包含式（I）化合物的药物组合物以及使用它们治疗糖尿病和其它与胰高血糖素相关的代谢紊乱等的方法。

公开(公告)号：US07943652B2

公开(公告)日：2011-05-17

申请号：US12411715

申请日：2009-03-26

申请人： Michael D. Shultz ,  Christine Hiu-Tung Chen ,  Young Shin Cho ,  Lei Jiang ,  Jianmei Fan ,  Gang Liu ,  Dyuti Majumdar ,  Jianke Li

发明人： Michael D. Shultz ,  Christine Hiu-Tung Chen ,  Young Shin Cho ,  Lei Jiang ,  Jianmei Fan ,  Gang Liu ,  Dyuti Majumdar ,  Jianke Li

IPC分类号： A61K31/4162 ,  A61K31/4155 ,  C07D487/04 ,  C07D231/10

CPC分类号： C07D207/08 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D471/04

摘要： The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐，水合物，酯和前药，其中R 1，R 2，R 3，Y，Z如本文所定义。 本教导还提供制备式I化合物的方法和使用式I化合物治疗，抑制或预防全部或部分由脱乙酰酶介导的病理状况或病症的方法。

公开(公告)号：US20080280982A1

公开(公告)日：2008-11-13

申请号：US12093486

申请日：2006-11-14

申请人： Jianke Li ,  Guoxin Zhu

发明人： Jianke Li ,  Guoxin Zhu

IPC分类号： A61K31/195 ,  C07C229/12 ,  A61P3/10

CPC分类号： C07C233/83

摘要： The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

摘要翻译： 本发明公开了具有胰高血糖素受体拮抗剂或反向激动剂活性的新颖的式I化合物或其药学上可接受的盐，以及制备这些化合物的方法。 在另一个实施方案中，本发明公开了包含式I化合物的药物组合物以及使用它们治疗糖尿病和其它与胰高血糖素相关的代谢紊乱等的方法。

公开(公告)号：US20080125468A1

公开(公告)日：2008-05-29

申请号：US11569273

申请日：2005-05-13

申请人： Mark Donald Chappell ,  Scott Eugene Conner ,  Isabel Cristina Gonzalez Valcarcel ,  Jason Eric Lamar ,  Jianke Li ,  Julie Sue Moyers ,  Rebecca Anne Owens ,  Allie Edward Tripp ,  Guoxin Zhu

发明人： Mark Donald Chappell ,  Scott Eugene Conner ,  Isabel Cristina Gonzalez Valcarcel ,  Jason Eric Lamar ,  Jianke Li ,  Julie Sue Moyers ,  Rebecca Anne Owens ,  Allie Edward Tripp ,  Guoxin Zhu

IPC分类号： A61K31/44 ,  C07D211/70 ,  A61P3/10 ,  A61K31/165 ,  C07C233/00

CPC分类号： C07D213/16 ,  C07D213/26 ,  C07D213/30 ,  C07D213/32 ,  C07D213/643 ,  C07D239/26 ,  C07D401/04

摘要： The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.